Scientists have tried to craft drugs that speed the elimination of the protein, α-synuclein, or prevent it from clumping. Neurologist and genomicist Clemens Scherzer of Harvard Medical School in Boston and colleagues decided to try a different strategy. “We wanted to find a drug that could turn down the production of α-synuclein,” he says. Read more about this research here.
